Log In Sign up
The largest database of trusted experimental protocols

Sars cov 2 total antibody assay

Manufactured by Roche
Visit Supplier

The SARS-CoV-2 total antibody assay is a serological test that detects the presence of antibodies against the SARS-CoV-2 virus. The assay is designed to qualitatively determine the presence of total antibodies, including IgM and IgG, in human serum or plasma samples.

Automatically generated - may contain errors

Lab products found in correlation

Advia centaur, by Siemens (3 mentions) E411 analyzer, by Siemens (2 mentions) Advia centaur xpt analyzer, by Siemens (2 mentions) E411 analyzer, by Roche (1 mentions)

Spelling variants of this product

Total anti-SARS-CoV-2 nucleocapsid antibody assay (2 citations) Elecsys Anti-SARS-CoV-2 S total antibody assay (2 citations) Anti-SARS-CoV-2 total antibody assay (2 citations)

3 protocols using sars cov 2 total antibody assay

1

SARS-CoV-2 Antibody Detection Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Nucleocapsid (N) antibodies were detected via the Elecsys (Roche) SARS-CoV-2 total antibody assay (“N immunoassay”) on a Cobas e411 analyzer and spike (S1-RBD or “S”) antibodies were detected via the ADVIA Centaur (Siemens) SARS-CoV-2 total (COV2T) assay (“S immunoassay”) on an ADVIA Centaur XPT analyzer in the Clinical Laboratory Improvement Amendments (CLIA)-certified U-M Clinical Pathology Laboratory. The assays detect the total SARS-CoV-2 nucleocapsid or spike receptor-binding domain antibodies via a sandwich electrochemiluminescence immunoassay (ECLIA) and chemiluminescence immunoassay (CLIA). A cutoff index (COI) of >1 is used to report a positive result. The assays detect all SARS-CoV-2 N or S antibodies, including IgG and IgM.
Schuler CF I.V., Gherasim C., O’Shea K., Manthei D.M., Chen J., Zettel C., Troost J.P., Kennedy A.A., Tai A.W., Giacherio D.A., Valdez R., Baldwin J.L, & Baker JR J.r. (2021). Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies. Microbiology Spectrum, 9(2), e00087-21.
+ Open protocol
+ Expand
2

SARS-CoV-2 Antibody Detection Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Nucleocapsid (N) antibodies were detected via the Elecsys (Roche) SARS-CoV-2 total antibody assay (“N immunoassay”) on a Cobas e411 analyzer and spike (S1-RBD or “S”) antibodies were detected via the ADVIA Centaur (Siemens) SARS-CoV-2 total (COV2T) assay (“S immunoassay”) on an ADVIA Centaur XPT analyzer in the Clinical Laboratory Improvement Amendments (CLIA)-certified U-M Clinical Pathology Laboratory. The assays detect the total SARS-CoV-2 nucleocapsid or spike receptor-binding domain antibodies via a sandwich electrochemiluminescence immunoassay (ECLIA) and chemiluminescence immunoassay (CLIA). A cutoff index (COI) of >1 is used to report a positive result. The assays detect all SARS-CoV-2 N or S antibodies, including IgG and IgM.
Schuler CF I.V., Gherasim C., O’Shea K., Manthei D.M., Chen J., Zettel C., Troost J.P., Kennedy A.A., Tai A.W., Giacherio D.A., Valdez R., Baldwin J.L, & Baker JR J.r. (2021). Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies. Microbiology Spectrum, 9(2), e00087-21.
+ Open protocol
+ Expand
3

Serological SARS-CoV-2 Antibody Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols
The Elecsys® (Roche) SARS-CoV-2 Total Antibody Assay on a Cobas e411 analyzer was used to detect anti-nucleocapsid antibodies. The ADVIA Centaur® (Siemens) SARS-CoV-2 Total (COV2T) assay on an ADVIA Centaur® XPT analyzer was used to detect anti-spike (S) antibodies. These assays detect total SARS-CoV-2 nucleocapsid or S antibodies via a sandwich electrochemiluminescence immunoassay or a chemiluminescence immunoassay, respectively. A cutoff index of >1 is defined as a positive result. The assays detect all isotypes in aggregate of the relevant SARS-CoV-2 antibody. All samples were evaluated in the CLIA-certified U-M Clinical Pathology Laboratory.
O’Shea K.M., Schuler CF I.V., Chen J., Troost J.P., Wong P.T., Chen K., O’Shea D.R., Peng W., Gherasim C., Manthei D.M., Valdez R., Baldwin J.L, & Baker JR J.r. (2023). Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing. Frontiers in Immunology, 14, 1055429.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!